Gain Therapeutics
GANX
GANX
26 hedge funds and large institutions have $7.04M invested in Gain Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
8% more funds holding
Funds holding: 24 → 26 (+2)
1.56% more ownership
Funds ownership: 7.57% → 9.13% (+1.6%)
Holders
26
Holding in Top 10
–
Calls
$85K
Puts
$60K
Top Buyers
| 1 | +$891K | |
| 2 | +$182K | |
| 3 | +$180K | |
| 4 |
Millennium Management
New York
|
+$119K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$117K |
Top Sellers
| 1 | -$231K | |
| 2 | -$84K | |
| 3 | -$60.7K | |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$51.9K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$37.4K |